ITEMS IN AFP WITH KEYWORD:
Education about promising physical therapies and treatments that may be on the horizon can be a source of encouragement for physicians and patients alike when facing a diagnosis of Parkinson disease.
Parkinson disease is a progressive neurologic disorder afflicting approximately 1 percent of Americans older than 60 years. The cardinal features of Parkinson disease are bradykinesia, rigidity, tremor, and postural instability. There are a number of neurologic conditions that mimic the disease, ma...
Dopamine agonists, such as pramipexole (Mirapex), ropinirole (Requip), pergolide (formerly Permax), and apomorphine (Apokyn), improve the motor fluctuations and dyskinesias that commonly occur with levodopa, but at the expense of increasing nonmotor adverse effects and noncompliance. An individual, case-based approach should be employed.
What are the effects of drug treatments in persons with early stage Parkinson's disease? What are the effects of adding other treatments in persons with motor complications from levodopa? What are the effects of surgery and nursing and rehabilitation treatments in persons with Parkinson's disease?
Mar 15, 2007 Issue
AAN Releases Recommendations on Treatment of Parkinson's Disease [Practice Guidelines]
Recommendations from the Quality Standards Subcommittee of the American Academy of Neurology (AAN) discuss aspects and treatment of Parkinson's disease. This condition is the second most common neurodegenerative disease and is characterized by bradykinesia; tremor at rest; rigidity; and abnormalities of balance, posture, and gait.
Parkinson's disease is a common neurodegenerative disorder that can cause significant disability and decreased quality of life. The cardinal physical signs of the disease are distal resting tremor, rigidity, bradykinesia, and asymmetric onset. Levodopa is the primary treatment for Parkinson's diseas...
Parkinson's disease is a progressive degenerative disorder of the central nervous system. The hallmark physical signs are tremor, rigidity and bradykinesia. Idiopathic Parkinson's disease is caused by the progressive loss of dopaminergic neurons in the substantia nigra and nigrostriatal pathway of t...